At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,409 enrolled
Drug / intervention
Alogliptin Benzoatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Local, Multicentre, Observational, Non-Interventional Prospective Study of Alogliptin Benzoate in Patients With Diabetes Mellitus Type 2
In Brief
An observational study evaluating Alogliptin Benzoate for Diabetes Mellitus. Completed, enrolled 1,409 participants across 53 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartSep 2016
Primary CompletionApr 2018
TodayJul 2026
First PostedApr 29, 2016
Enrollment StartSep 20, 2016
Primary CompletionApr 28, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.2 years ago
Interventions
Alogliptin Benzoatedrug
Alogliptin benzoate tablets